Congenital Bile Acid Synthesis Defect 3

Congenital bile acid synthesis defect 3, also called CBAS3 or oxysterol 7 alpha-hydroxylase deficiency, is a very rare inherited liver disease caused by harmful changes in the CYP7B1 gene. This gene helps the liver make normal bile acids. When the enzyme does not work well, the body makes abnormal bile acid intermediates instead of enough normal bile acids. These abnormal chemicals can injure the liver, reduce bile flow, and make it hard to absorb fats and vitamins A, D, E, and K. Babies may develop jaundice, poor weight gain, pale stools, enlarged liver, bleeding risk, and progressive liver scarring. Some people with CYP7B1 changes can also develop a later neurologic problem called hereditary spastic paraplegia type 5.

Congenital bile acid synthesis defect 3 is a very rare inherited liver disease. It is also called CBAS3 or bile acid synthesis defect, congenital, 3. In this disease, the body cannot make some bile acids in the normal way because the CYP7B1 gene does not work properly. This gene helps the body make an enzyme called oxysterol 7-alpha-hydroxylase. That enzyme is part of one of the pathways used to turn cholesterol into bile acids. When this step fails, the liver makes abnormal bile acid products instead of enough normal bile acids. These abnormal products can injure the liver, reduce bile flow, and lead to cholestasis, which means bile cannot move out of the liver in the right way.

This condition usually starts in newborns or very young infants. Many babies develop long-lasting jaundice, enlarged liver, direct hyperbilirubinemia, and progressive liver disease. Some infants become very sick early, while others are diagnosed after a delay. Because the disease is rare and can look like other causes of infant liver disease, doctors may miss it at first. Early diagnosis matters because delayed diagnosis can allow fibrosis, cirrhosis, liver failure, or even death to develop.

The strongest evidence-based treatment goal is to restore a healthier bile acid pool, reduce toxic abnormal bile acids, improve bile flow, support nutrition, correct vitamin deficiency, and prevent liver failure. For CBAS3 specifically, a major pediatric cholestasis review notes that chenodeoxycholic acid may be effective, and published case reports describe survival and liver improvement with oral chenodeoxycholic acid in some infants. FDA-approved cholic acid (CHOLBAM) is approved for bile acid synthesis disorders due to single-enzyme defects as a group, but published CBAS3-specific evidence is much stronger for chenodeoxycholic acid than for cholic acid. In severe cases with advanced liver failure, liver transplantation can be lifesaving.

This disease is usually inherited in an autosomal recessive way. That means the child gets one nonworking copy of the gene from each parent. The parents are often healthy carriers. The main disease gene is CYP7B1, located on chromosome 8. Orphanet and the NIH genetic sources identify congenital bile acid synthesis defect type 3 as the form caused by CYP7B1 mutation, and clinical genetic test registries list the same gene-disease link.

Another names

Congenital bile acid synthesis defect 3 is also known by several closely related names. These names all refer to the same rare disorder or to the same enzyme problem that causes it.

1. Congenital bile acid synthesis defect type 3.
2. Bile acid synthesis defect, congenital, 3.
3. Oxysterol 7-alpha-hydroxylase deficiency.
4. CYP7B1 deficiency with infantile cholestatic liver disease. This is a descriptive medical name based on the disease gene and liver presentation.

Types

This disorder is mainly recognized as one specific type of congenital bile acid synthesis defect, namely type 3, caused by CYP7B1 variants. In practical clinical use, doctors may still describe the patient in subgroups according to the way the disease appears.

List view of practical clinical types:

1. Infantile hepatic form with cholestasis and liver disease in early life.
2. Severe early progressive form with fast worsening, fibrosis, liver failure, or need for transplant.
3. Milder or later-recognized form where diagnosis is delayed because findings are less obvious at first.

Causes

Strictly speaking, this disease has one main root cause: a child inherits disease-causing variants in both copies of the CYP7B1 gene. Still, to match your requested format, here are 20 cause-related points that explain how the disease begins and why liver damage happens.

1. CYP7B1 gene mutation. This is the main direct cause. The gene cannot make the enzyme work normally.

2. Oxysterol 7-alpha-hydroxylase deficiency. The missing or weak enzyme causes failure in bile acid production through an alternative pathway.

3. Autosomal recessive inheritance. The child usually becomes sick only after receiving two altered gene copies, one from each parent.

4. Carrier parents. Healthy parents may carry one changed gene each and not know it.

5. Homozygous mutation. Some children inherit the same harmful variant from both parents.

6. Compound heterozygous mutation. Some children inherit two different harmful CYP7B1 variants.

7. Nonsense mutation. A mutation can create an early stop signal, so the protein is too short and cannot work.

8. Frameshift mutation. A small insertion or deletion can shift the reading frame and badly damage the enzyme.

9. Missense mutation. One DNA letter change can alter one amino acid and weaken enzyme function.

10. Splice-site mutation. A mutation can make the body build the gene message incorrectly.

11. Reduced bile acid synthesis. Less normal bile acid is made, so bile flow becomes poor.

12. Build-up of abnormal bile acid intermediates. These abnormal products can be toxic to liver cells.

13. Impaired bile flow. Poor bile flow causes cholestasis, which is a major step in the disease process.

14. Liver cell injury. Abnormal metabolites can injure hepatocytes and worsen inflammation.

15. Progressive fibrosis. Ongoing liver injury leads to scarring over time.

16. Fat malabsorption. Lack of normal bile acids reduces fat digestion and can worsen the child’s overall condition.

17. Fat-soluble vitamin deficiency. Vitamins A, D, E, and K may not be absorbed well, adding more problems.

18. Delayed diagnosis. The disease can progress when it is not recognized early.

19. Family recurrence risk. Brothers or sisters may also be affected because the inheritance pattern repeats in pregnancies.

20. Consanguinity in some families. In recessive diseases, parents who are related may have a higher chance of carrying the same harmful variant. This is a general genetic risk principle for autosomal recessive disorders.

Symptoms

The symptoms usually come from cholestasis, poor bile acid production, fat malabsorption, and liver injury. Some babies show many symptoms, while others show only a few at first.

1. Prolonged jaundice. The skin and eyes stay yellow longer than expected after birth. This is one of the most common warning signs.

2. Dark urine. Excess conjugated bilirubin can make the urine dark.

3. Pale or clay-colored stools. Poor bile reaching the intestine can make stools look pale.

4. Enlarged liver. Doctors may feel a large liver on examination.

5. Enlarged spleen. Some patients develop splenomegaly, especially if liver disease advances.

6. Poor weight gain. Babies may fail to grow well because they cannot absorb fats and vitamins normally.

7. Fatty stools or steatorrhea. Poor bile acid function may lead to greasy or bulky stool.

8. Easy bleeding or bruising. Vitamin K deficiency and liver dysfunction can affect clotting.

9. Poor feeding. Sick infants may feed badly because of liver illness.

10. Irritability. Babies may be fussy or uncomfortable, though this sign is not specific.

11. Tiredness or low activity. Liver disease and poor nutrition can make the child weak.

12. Itching. Cholestasis can cause itching, though it may be harder to notice in very young infants.

13. Swollen belly. Hepatomegaly, splenomegaly, or fluid build-up can enlarge the abdomen.

14. Signs of liver failure. In severe cases, babies may develop worsening jaundice, coagulopathy, and serious illness.

15. Vitamin deficiency signs. These may include poor growth, bone problems, vision issues, or neurologic problems depending on which vitamin is low.

Diagnostic tests

Diagnosis usually needs a combination of history, examination, blood tests, bile acid studies, imaging, and genetic testing. A very important clue is cholestasis with normal or near-normal GGT, because this pattern can suggest a bile acid synthesis disorder.

1. General inspection for jaundice. The doctor looks for yellow skin and yellow eyes. This is a simple but important first clue that bilirubin is high.
2. Liver size check. The doctor feels the abdomen to see whether the liver is enlarged. Hepatomegaly is common in CBAS3.
3. Spleen size check. The doctor checks whether the spleen is enlarged. This may suggest more advanced liver disease or portal hypertension.
4. Growth assessment. Weight, length, and head growth are measured. Poor growth can support chronic cholestatic disease with malabsorption.
5. Abdominal palpation. This hands-on exam helps the doctor feel liver edge, spleen edge, belly fullness, and tenderness
6. Stool and urine color review. The doctor asks parents about pale stool and dark urine. This helps confirm cholestasis in a very practical way.
7. Nutrition and feeding assessment. The clinician asks about feeding, vomiting, stool fat, and weight gain. These details help show how much the disease is affecting digestion and growth.
8. Total bilirubin and direct bilirubin. These are core cholestasis tests. Direct bilirubin is usually high in infant cholestatic disease.
9. ALT and AST. These liver enzymes often rise when liver cells are injured. Many reported cases show elevated aminotransferases.
10. GGT. In CBAS3, GGT may be normal or near normal despite significant cholestasis. This pattern is an important clue.
11. Total bile acids. These may be normal or nearly normal in some reported CBAS3 patients, which can be surprising.
12. Albumin. Low albumin can suggest reduced liver synthetic function or poor nutrition.
13. Prothrombin time and INR. These tests show whether the liver can help make clotting proteins. They also help detect vitamin K-related bleeding risk.
14. Fat-soluble vitamin levels. Vitamins A, D, E, and K may be low in bile acid disorders because fat absorption is poor.
15. Urine bile acid analysis by mass spectrometry. This is one of the most important specialized tests. It looks for abnormal bile acid intermediates and can strongly suggest a bile acid synthesis defect.
16. Serum bile acid profiling. This test studies the bile acid pattern in blood and can support the diagnosis when abnormal intermediates are present.
17. Genetic testing for CYP7B1. This is the confirmatory test. Single-gene testing, cholestasis panels, or exome testing may detect the disease-causing variants.
18. Liver biopsy. Biopsy can show cholestasis, giant cell change, fibrosis, and other liver injury patterns. It is helpful in difficult cases, although newer algorithms often use genetic testing earlier.
19. No routine electrodiagnostic test is primary for diagnosis. This disease is mainly a liver and metabolic disorder, so tests such as EEG, EMG, or nerve conduction studies are not standard first-line tests for infant liver diagnosis. In rare later neurologic CYP7B1-related disease, neurologic testing may be used, but it is not a core test for infantile CBAS3 cholestasis.
20. Abdominal ultrasound. Ultrasound helps check liver size, spleen size, gallbladder, bile ducts, and signs that point toward or away from biliary atresia or other structural disease. It is a routine part of cholestasis work-up.

Non-pharmacological treatments

1. Early specialist follow-up means regular care with a pediatric hepatologist, metabolic specialist, dietitian, and genetic counselor. The purpose is early diagnosis and early action. The mechanism is simple: frequent review helps doctors track jaundice, growth, stool color, vitamin status, and liver injury before damage becomes permanent.

2. Genetic confirmation of CYP7B1 helps confirm the exact disorder. The purpose is diagnostic certainty. The mechanism is that gene testing separates CBAS3 from other causes of neonatal cholestasis, which matters because treatment choice and family counseling depend on the exact defect.

3. Urine bile acid mass spectrometry is a key diagnostic therapy-support tool. The purpose is to find abnormal bile acid patterns. The mechanism is direct chemical detection of unusual hepatotoxic bile acid intermediates, which supports diagnosis and can help monitor response.

4. Growth monitoring means checking weight, length, head growth, and feeding tolerance often. The purpose is to catch malnutrition early. The mechanism is that cholestasis reduces fat absorption, so poor growth can be one of the earliest signs that nutrition support must be strengthened.

5. High-calorie feeding plans are used when growth is poor. The purpose is to provide enough energy for healing and growth. The mechanism is simple: babies with liver disease often need more calories because absorption is poor and illness increases energy needs.

6. Medium-chain triglyceride focused nutrition is often helpful. The purpose is better fat absorption. The mechanism is that MCT fat is absorbed more easily than many long-chain fats when bile flow is low, so it can improve calorie delivery.

7. Breastfeeding or medically adjusted formula support may still be used with close monitoring. The purpose is safe feeding. The mechanism is individual tailoring of fat composition and calorie density to maintain growth without worsening malabsorption.

8. Fat-soluble vitamin monitoring is essential even before clear deficiency appears. The purpose is prevention of bleeding, bone disease, vision problems, and nerve injury. The mechanism is frequent blood testing because cholestasis reduces vitamin absorption.

9. Sunlight and bone-health support are supportive measures. The purpose is stronger bones. The mechanism is indirect: vitamin D deficiency and cholestasis can weaken bone, so monitored sun exposure, nutrition, and supplements may support bone health.

10. Bleeding-risk precautions include avoiding trauma and checking clotting status. The purpose is safety. The mechanism is that vitamin K deficiency and liver dysfunction can increase bleeding, so prevention lowers emergency risk.

11. Itch skin care includes cool baths, soft cotton clothes, trimmed nails, and moisturizers. The purpose is comfort. The mechanism is reduction of skin injury from scratching, which is important in cholestatic liver disease.

12. Infection prevention includes hand hygiene, vaccines advised by the care team, and quick review of fever. The purpose is to protect a vulnerable child with liver disease. The mechanism is fewer infectious stresses on an already injured liver.

13. Hospital nutrition team review helps when feeding becomes difficult. The purpose is organized long-term nutrition care. The mechanism is combining calorie planning, vitamin replacement, and growth checks in one plan.

14. Regular liver ultrasound and labs help track fibrosis and portal hypertension. The purpose is to watch progression. The mechanism is repeated imaging and blood work to detect worsening before crisis develops.

15. Stool and urine color observation at home can be useful. The purpose is early warning. The mechanism is that pale stools, dark urine, or worsening jaundice can suggest poor bile flow and need urgent review.

16. Parental education is a real treatment tool. The purpose is safer daily care. The mechanism is that parents who know warning signs seek help earlier and improve adherence to diet, vitamins, and medicines.

17. Genetic counseling for family planning is important. The purpose is to explain recurrence risk. The mechanism is education about autosomal recessive inheritance and testing options for relatives or future pregnancies.

18. Developmental follow-up is important because CYP7B1 can also be linked to later neurologic disease in some people. The purpose is early detection of weakness or stiffness. The mechanism is routine neurologic review over time.

19. Liver transplant evaluation when disease worsens is a non-drug management step. The purpose is planning before emergency failure. The mechanism is early referral so the child is assessed before severe decompensation.

20. Long-term adherence support means making feeding and medicine routines easy for the family. The purpose is steady treatment effect. The mechanism is better day-to-day consistency, which is critical in rare metabolic liver disease.

Drug treatments

Important note: CBAS3 has very few disease-specific medicines with direct evidence. The medicines below include one disease-directed FDA-approved therapy class, one CBAS3-focused off-label bile acid therapy supported by case reports, and supportive drugs commonly used in cholestasis or advanced liver disease when specific symptoms appear. They are not all routine for every patient. Doses must be individualized by a specialist.

1. Cholic acid (CHOLBAM) is the main FDA-approved bile acid replacement drug for bile acid synthesis disorders due to single-enzyme defects. Class: bile acid. Dose: FDA label recommends 10 to 15 mg/kg/day by mouth once daily or in two divided doses. Purpose: replace missing primary bile acids and suppress production of toxic abnormal intermediates. Mechanism: restored bile acid feedback reduces abnormal synthesis and may improve bile flow. Important side effects include diarrhea, reflux, malaise, jaundice worsening, skin lesions, and abnormal liver tests; liver monitoring is required.

2. Chenodeoxycholic acid / chenodiol is the most important CBAS3-specific evidence-based option, but it is generally off-label for this disease. Class: primary bile acid. Dose in case reports varies and must be specialist-set. Purpose: provide a more physiologic bile acid signal in CYP7B1 deficiency. Mechanism: replacement suppresses toxic atypical bile acid production and improves bile acid homeostasis. Side effects can include diarrhea and dose-related liver toxicity, so close monitoring is needed. Published CBAS3 infant cases showed biochemical and clinical improvement.

3. Ursodiol / ursodeoxycholic acid is sometimes tried before diagnosis or for cholestasis support, but it is not the best evidence-based disease-correcting treatment for CBAS3. Class: hydrophilic bile acid. Purpose: improve bile flow in some cholestatic settings. Mechanism: makes bile less toxic and may improve secretion. In one CBAS3 case report, the child worsened while on UDCA before more specific therapy. Side effects usually include diarrhea or abdominal upset. Use is case by case.

4. Vitamin K (phytonadione) is used when clotting is impaired or deficiency is suspected. Class: fat-soluble vitamin/hemostatic support. Purpose: reduce bleeding risk. Mechanism: restores hepatic production of clotting factors that depend on vitamin K. Side effects are usually mild, but route and dose depend on the severity of coagulopathy and absorption problems.

5. Vitamin D preparations are often needed because cholestasis reduces absorption. Class: vitamin supplement. Purpose: protect bones and calcium balance. Mechanism: improves intestinal calcium handling and bone mineralization. Side effects depend on dose and can include high calcium if overused.

6. Vitamin A may be required in deficiency. Class: fat-soluble vitamin. Purpose: protect vision, skin, and immunity. Mechanism: replaces missing stores when fat absorption is poor. Side effects of excess include liver toxicity and raised intracranial pressure, so specialist monitoring is important.

7. Vitamin E may be needed for neurologic and antioxidant support in deficiency. Class: fat-soluble vitamin. Purpose: reduce deficiency-related nerve and muscle complications. Mechanism: membrane antioxidant replacement. Side effects at high doses can include bleeding risk.

8. Multivitamin preparations designed for cholestasis may be used. Class: combined vitamin product. Purpose: easier replacement of multiple deficiencies. Mechanism: gives concentrated absorbable micronutrients in one plan. Side effects depend on formula and dose.

9. Cholestyramine may be used if itch becomes a major symptom. Class: bile acid sequestrant. Purpose: reduce cholestatic pruritus. Mechanism: binds bile acids in the gut and lowers reabsorption. Side effects include constipation, bloating, poor taste, and reduced absorption of other medicines and vitamins; it should be timed apart from other oral drugs.

10. Rifampin can be used for difficult cholestatic itch. Class: rifamycin/PXR activator. Purpose: reduce severe pruritus. Mechanism: changes metabolism and transport of itch-related compounds. Side effects include hepatotoxicity, drug interactions, orange body fluids, and rash, so it needs careful liver monitoring.

11. Naltrexone is another option for refractory itch in selected cases. Class: opioid antagonist. Purpose: reduce itching when first-line approaches fail. Mechanism: blocks opioid-related itch signaling. Side effects may include nausea, abdominal pain, headache, or withdrawal-like symptoms in some settings.

12. Sertraline may be considered for persistent cholestatic itch. Class: SSRI. Purpose: symptom control. Mechanism: central modulation of itch pathways. Side effects can include nausea, sleep change, and behavior effects. Evidence is supportive, not CBAS3-specific.

13. Hydroxyzine can help with itch discomfort and sleep. Class: antihistamine. Purpose: symptom relief, especially at night. Mechanism: sedation and antihistamine effect, although cholestatic itch is not mainly histamine-driven. Side effects include sleepiness and dry mouth.

14. Albumin infusion may be used short term in decompensated illness. Class: plasma volume support. Purpose: support circulation or severe hypoalbuminemia. Mechanism: raises oncotic pressure. It is supportive only and does not correct CBAS3.

15. Diuretics such as spironolactone may be used if ascites develops. Class: potassium-sparing diuretic. Purpose: remove extra fluid. Mechanism: blocks aldosterone effect in the kidney. Side effects include high potassium and dehydration.

16. Furosemide may be added for ascites or edema in selected patients. Class: loop diuretic. Purpose: fluid control. Mechanism: increases sodium and water excretion. Side effects include dehydration, low potassium, and kidney stress.

17. Lactulose may be used if hepatic encephalopathy develops in advanced liver failure. Class: osmotic disaccharide. Purpose: lower ammonia. Mechanism: traps ammonia in the colon and promotes excretion. Side effects include diarrhea and bloating.

18. Antibiotics such as rifaximin may be added in encephalopathy care. Class: gut-selective antibiotic. Purpose: reduce ammonia-producing bacteria. Mechanism: changes gut bacterial load. This is not disease-specific and is used only in advanced liver disease.

19. Proton pump inhibitors may be used if reflux, ulcer risk, or feeding discomfort appears. Class: acid suppressor. Purpose: symptom relief. Mechanism: lowers stomach acid. This is supportive only, not disease-correcting.

20. Fat-soluble vitamin injections or higher-intensity replacement may be needed when oral absorption is poor. Class: deficiency-correction therapy. Purpose: bypass severe malabsorption. Mechanism: improves body stores despite cholestasis.

Dietary molecular supplements

1. MCT oil is the most practical nutrition supplement in cholestasis. It gives calories that are absorbed more easily than many long-chain fats. It is functional because it helps energy intake when bile flow is low. Its mechanism is easier intestinal absorption with less need for normal micelle formation. Dosing varies; published guidance in infants often mentions about 1 to 2 mL/kg/day, adjusted by the care team.

2. Vitamin A supplement supports vision, skin, and immune function when fat absorption is poor. Its function is replacement of a common deficiency risk. The mechanism is restoration of retinoid stores and epithelial function. Dose must be individualized because too much vitamin A can also injure the liver.

3. Vitamin D supplement supports bone mineralization and calcium balance. Its function is prevention of rickets and weak bones. The mechanism is improved calcium absorption and bone metabolism. Dose depends on age and blood levels.

4. Vitamin E supplement supports nerve and muscle health. Its function is antioxidant replacement in cholestatic malabsorption. The mechanism is protection of cell membranes from oxidative injury. Dose is adjusted to lab response and clinical need.

5. Vitamin K supplement supports clotting. Its function is bleeding prevention. The mechanism is activation of clotting factor synthesis. Dose and route are individualized, especially if jaundice and malabsorption are severe.

6. Calcium may be added when bone health is at risk. Its function is skeletal support. The mechanism is providing the mineral needed for bone structure, especially when vitamin D deficiency has been present.

7. Zinc may be supplemented if intake or labs suggest deficiency. Its function is growth and wound support. The mechanism is enzyme and immune support. It is supportive, not disease-specific.

8. Selenium can be considered in prolonged malnutrition. Its function is antioxidant enzyme support. The mechanism is support of selenoproteins. Use depends on diet and laboratory review.

9. Essential fatty acid supplementation may be needed if MCT intake is high for a long time. Its function is prevent essential fatty acid deficiency. The mechanism is replacing fats the body cannot make.

10. Protein-calorie modular supplements may be needed in poor growth. Their function is catch-up growth. The mechanism is delivering more calories and protein in a smaller volume.

Immunity booster, regenerative, or stem-cell drugs

At present, there are no FDA-approved immunity-booster drugs, regenerative drugs, or stem-cell drugs proven to treat CBAS3 itself. I should be very clear here because accuracy matters. Published evidence for CBAS3 supports bile acid replacement, nutrition correction, and transplantation in advanced disease. Stem-cell therapy for CBAS3 is not standard care.

1. No approved immune booster for CBAS3. Infection prevention and nutrition are more important than so-called immunity boosters.

2. No approved liver regenerative drug for CBAS3. Improvement comes from removing toxic bile acid stress and supporting the liver, not from a proven regeneration medicine.

3. No approved stem-cell drug for CBAS3. It remains investigational and is not standard evidence-based care.

4. Vitamin-based support is not an immune booster drug. It corrects deficiency but does not specifically cure the metabolic defect.

5. Albumin is not regenerative therapy. It can support circulation temporarily in severe illness only.

6. Liver transplantation is the established rescue option, not stem-cell treatment, when liver failure becomes advanced.

Surgeries or procedures

1. Liver transplantation is the most important surgery when liver failure, severe fibrosis, or decompensation occurs. It is done to replace the failing liver and can normalize liver function in severe CBAS3.

2. Living donor liver transplantation is a form of transplant often used in infants and children. It is done because organs are limited and early transplant can save life before further decline.

3. Liver biopsy is a procedure, not a cure, but it may be done to assess fibrosis and exclude other causes of cholestasis. It helps guide diagnosis and urgency.

4. Central venous access placement may be needed in very sick infants for nutrition, blood products, or repeated treatment. It is done to support safe hospital care.

5. Endoscopy for varices may be needed in advanced portal hypertension. It is done to diagnose or treat enlarged bleeding veins related to chronic liver scarring.

Prevention tips

CBAS3 is genetic, so the disease itself cannot usually be prevented after conception, but complications can often be reduced by early diagnosis, early bile acid therapy, good nutrition, vitamin replacement, and close follow-up.

Prevent late diagnosis, prevent severe malnutrition, prevent vitamin deficiency, prevent bleeding, prevent dehydration, prevent skin injury from scratching, prevent delayed transplant referral, prevent missed neurologic follow-up, prevent unsafe over-the-counter “liver cures,” and prevent medicine interactions by checking every new product with the liver team.

When to see a doctor

See a doctor urgently for new jaundice, pale or white stools, dark urine, poor feeding, poor weight gain, vomiting, bleeding, swollen belly, fever, severe itching, sleepiness, confusion, or reduced urine. In a known CBAS3 patient, any worsening of jaundice, bruising, edema, or feeding should trigger prompt review.

What to eat and what to avoid

Eat or use: breast milk or specialist formula as advised, MCT-enriched feeds if prescribed, enough calories, enough protein, prescribed fat-soluble vitamins, and regular hydration. Avoid: unplanned fasting, very low-calorie diets, unmonitored herbal liver products, alcohol in older patients, excess vitamin A without supervision, and high-MCT plans without essential fatty acid review.

FAQs

What is the main cause? CBAS3 is caused by harmful variants in CYP7B1.

Is it inherited? Yes. It is usually autosomal recessive, so both parents are often healthy carriers.

What does the enzyme normally do? It helps make normal bile acids from cholesterol-related molecules.

Why does jaundice happen? Damaged bile acid production leads to cholestasis and liver injury.

Why are vitamins low? Low bile flow reduces absorption of vitamins A, D, E, and K.

What is the best proven medicine? For bile acid synthesis disorders broadly, FDA-approved cholic acid is established; for CBAS3 specifically, published reports suggest chenodeoxycholic acid may be effective.

Can it be cured with diet alone? No. Diet helps, but it does not fix the genetic enzyme defect.

Can it lead to liver failure? Yes, especially in infancy if untreated or diagnosed late.

Can transplant help? Yes. In severe disease, liver transplantation can be lifesaving.

Can adults have problems too? Yes. Some CYP7B1-related disease appears later as neurologic problems such as hereditary spastic paraplegia type 5.

Is itching always present? No. Some patients have cholestatic itch, but not all.

Should families get counseling? Yes. Genetic counseling is strongly useful.

Are stem cells standard treatment? No. They are not established care for CBAS3.

Can over-the-counter supplements replace medical care? No. They may miss the real disease and delay lifesaving treatment.

What is the outlook? Prognosis improves with early recognition, targeted bile acid therapy, nutrition support, and transplant when needed.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: March 10, 2025.